Ally Bridge Group
Private equity
Active
New York, United States
80
82M
58
7.27
14
0.24
21
- Stages of investment
- Areas of investment
Summary
In 2013 was created Ally Bridge Group, which is appeared as VC. The main office of represented VC is situated in the Hong Kong. The company was established in Asia in Hong Kong.
Among the various public portfolio startups of the fund, we may underline TESARO, GRAIL, Innovent Biologics Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Pharmaceutical. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 26 percentage points more often commits exit comparing to other companies. Opposing the other organizations, this Ally Bridge Group works on 0 percentage points more the average amount of lead investments. The higher amount of exits for fund were in 2018. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. Deals in the range of 50 - 100 millions dollars are the general things for fund. The average startup value when the investment from Ally Bridge Group is 500 millions - 1 billion dollars.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Ally Bridge Group, startups are often financed by New Enterprise Associates, Kleiner Perkins, F-Prime Capital. The meaningful sponsors for the fund in investment in the same round are Rock Springs Capital, New Enterprise Associates, Hillhouse Capital Group. In the next rounds fund is usually obtained by Venrock, T. Rowe Price, Sofinnova Partners.
This organization was formed by Frank Yu. The overall number of key employees were 3.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 80
- Lead investments
- 14
- Exits
- 21
- Rounds per year
- 7.27
- Follow on index
- 0.24
- Investments by industry
- Health Care (55)
- Biotechnology (53)
- Medical Device (24)
- Medical (23)
- Pharmaceutical (21) Show 30 more
- Investments by region
-
- United States (54)
- China (12)
- Ireland (2)
- Canada (3)
- United Kingdom (1) Show 2 more
- Peak activity year
- 2021
- Number of Unicorns
- 3
- Number of Decacorns
- 3
- Number of Minotaurs
- 4
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 251M
- Group Appearance index
- 0.90
- Avg. company exit year
- 4
- Avg. multiplicator
- 3.10
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Ceribell | 21 Sep 2022 | Biotechnology, Health Care, Health Diagnostics, Medical Device | Late Stage Venture | 50M | United States, California, Mountain View |
Deltafour | 01 Apr 2023 | Analytics, Artificial Intelligence, Service Industry | Seed | Bangalore, Karnataka, India | |
ImmunGene | 07 Nov 2013 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 9M | United States, California |
06 May 2015 | Small and Medium Businesses, Marketing, Social Media, Advertising, SEO | Post-IPO Debt | 25M | United States, Los Angeles | |
YouCKU.com | 01 Apr 2019 | Automotive, Leasing | Early Stage Venture | 7M | China, Guangdong Province, Futian District |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.